First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 3002-3011

  Gridelli, Cesare ^a   Ciardiello, Fortunato ^b   Gallo, Ciro ^b   Feld, Ronald ⁿ   Butts, Charles ^q   Gebbia, Vittorio ^g   Maione, Paolo ^a   Morgillo, Floriana ^b   Genestreti, Giovenzio ^h   Favaretto, Adolfo ⁱ   Leighl, Natasha ⁿ   Wierzbicki, Rafal ^o   Cinieri, Saverio ^j,k   Alam, Yasmin ^p   Siena, Salvatore ^l   Tortora, Giampaolo ^c,f   Felletti, Raffaella ^m   Riccardi, Ferdinando ^d   Mancuso, Gianfranco ^g   Rossi, Antonio ^a   Cantile, Flavia ^b   Tsao, Ming Sound ⁿ   Saieg, Mauro ⁿ   Santos, Gilda Da Cunha ⁿ   Piccirillo, Maria Carmela ^e   Di Maio, Massimo ^e   Morabito, Alessandro ^e   Perrone, Francesco ^e   more..

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g LA MADDALENA CANCER CENTER   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j A Perrino Hospital   (Italy)

^k EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^l OSPEDALE NIGUARDA CA GRANDA   (Italy)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ PRINCESS MARGARET HOSPITAL   (Canada)

^o Oncology Clinical Trials Durham Regional Cancer Centre   (Canada)

^p Centre Regional De Cancerologie De Windsor   (Canada)

^q CROSS CANCER INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HAIR LOSS; HAZARD RATIO; HEART ARRHYTHMIA; HEART DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SAMPLE SIZE; SIDE EFFECT; SMOKING HABIT; THROMBOCYTOPENIA; VASCULAR DISEASE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865154870     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.2056     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. [No authors listed]: Chemotherapy in nonsmall cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
3. NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617-4625, 2008
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
5. Cardenal F, López-Cabrerizo MP, Antón A, et al: Randomized phase III study of gemcitabinecisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12-18, 1999
6. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cis-platin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000 (Pubitemid 30036345)
7. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
9. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005 (Pubitemid 41058345)
10. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
11. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
12. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al: Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study. Clin Cancer Res 12:6049-6055, 2006 (Pubitemid 44703768)
13. Jackman DM, Yeap BY, Lindeman NI, et al: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760-766, 2007 (Pubitemid 350002874)
14. Pan Q, Pao W, Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7:396-403, 2005 (Pubitemid 41149655)
15. Lara-Guerra H, Waddell TK, Salvarrey MA, et al: Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 27:6229-6236, 2009
16. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
17. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005 (Pubitemid 41540110)
18. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-smallcell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011
19. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
20. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
21. Sequist LV, Martins RG, Spigel D, et al: Firstline gefitinib in patients with advanced non-smallcell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
22. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
23. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497- 1500, 2004
24. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005 (Pubitemid 47050841)
25. Park K, Goto K: A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 22: 561-573, 2006
26. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
27. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362:2380- 2388, 2010
28. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
29. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
30. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009